- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.07. | TScan Therapeutics wählt Direktoren und bestätigt Wirtschaftsprüfer bei Jahreshauptversammlung | 1 | Investing.com Deutsch | ||
| 02.07. | TScan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | What Analysts Are Saying About TScan Therapeutics Stock | 4 | Benzinga.com | ||
| 07.05. | H.C. Wainwright cuts Tscan stock target to $10, keeps Buy rating | 2 | Investing.com | ||
| 06.05. | TScan Therapeutics GAAP EPS of $0.26 | 5 | Seeking Alpha | ||
| 06.05. | TScan Therapeutics May 2025 slides: advancing TCR-T therapies with positive Phase 1 data | 2 | Investing.com | ||
| 06.05. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.04. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 08.04. | Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts | 1 | Benzinga.com | ||
| 27.03. | TScan Therapeutics, Inc.: TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access | 2 | GlobeNewswire (USA) | ||
| 06.03. | Breaking Down TScan Therapeutics: 4 Analysts Share Their Views | 1 | Benzinga.com | ||
| 05.03. | TScan Therapeutics files for $300M mixed securities shelf | 2 | Seeking Alpha | ||
| 05.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.03. | TScan Therapeutics GAAP EPS of $0.30, revenue of $0.67M | 1 | Seeking Alpha | ||
| 05.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 05.03. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.08.24 | TScan Therapeutics, Inc.: TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | 213 | GlobeNewswire (Europe) | FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| MEDIGENE | 0,121 | -8,36 % | PTA-Adhoc: Medigene AG: Ausscheiden des Vorstandsvorsitzenden Dr. Selwyn Ho und Bestellung von Ralph Schäfer als Vorstand | DJ PTA-Adhoc: Medigene AG: Ausscheiden des Vorstandsvorsitzenden Dr. Selwyn Ho und Bestellung von Ralph Schäfer als Vorstand
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
... ► Artikel lesen | |
| AMGEN | 253,90 | +0,10 % | Amgen: Robustes Pharma-Geschäft und Dividende | Die Amgen-Aktie stellt eine attraktive Depotbeimischung für jedes diversifizierte oder Pharma-orientierte Anlegerdepot dar. Die Bewertung ist vergleichsweise günstig, die Aussichten stabil. Und es gibt... ► Artikel lesen | |
| BIOFRONTERA | 2,450 | +0,41 % | Biofrontera files to sell 13.6M shares of common stock by selling shareholders | ||
| BIOGEN | 107,50 | -0,09 % | Here's What to Expect From Biogen's Next Earnings Report | ||
| REGENERON PHARMACEUTICALS | 466,50 | -0,04 % | Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold? | ||
| EDITAS MEDICINE | 2,360 | -0,46 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| GALAPAGOS NV | 27,000 | +0,75 % | Galapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer | Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated... ► Artikel lesen | |
| IMMATICS | 5,185 | +0,39 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
| AYALA PHARMACEUTICALS | 0,010 | 0,00 % | OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 2,100 | +0,96 % | Autolus Therapeutics plc: Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering... ► Artikel lesen | |
| IGM BIOSCIENCES | 1,110 | +0,91 % | IGM Biosciences, Inc.: IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right | MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today... ► Artikel lesen | |
| ONCOPEPTIDES | 0,280 | -6,52 % | Oncopeptides AB: Oncopeptides announces net sales for Q2 2025 | Stockholm, July 9, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the second quarter of 2025.
Oncopeptides... ► Artikel lesen | |
| AVACTA | 0,400 | +12,36 % | Avacta Group raises £3.25 million through share placing |
Das Unternehmen TSCAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,95 % bei einem Aktienkurs von 1,810 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.